| Original language | English |
|---|---|
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| DOIs | |
| Publication status | Accepted/In press - 2021 |
ASJC Scopus subject areas
- Immunology and Allergy
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Aspergillus-related diseases in a cohort of patients with severe asthma : A SANI single-center report. / Solidoro, Paolo; Nicola, Stefania; Ridolfi, Irene; Bucca, Caterina; Heffler, Enrico; Bagnasco, Diego; Canonica, Giorgio Walter; Blasi, Francesco; Paggiaro, Pierluigi; Rolla, Giovanni; Brussino, Luisa.
In: Journal of Allergy and Clinical Immunology: In Practice, 2021.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Aspergillus-related diseases in a cohort of patients with severe asthma
T2 - A SANI single-center report
AU - Solidoro, Paolo
AU - Nicola, Stefania
AU - Ridolfi, Irene
AU - Bucca, Caterina
AU - Heffler, Enrico
AU - Bagnasco, Diego
AU - Canonica, Giorgio Walter
AU - Blasi, Francesco
AU - Paggiaro, Pierluigi
AU - Rolla, Giovanni
AU - Brussino, Luisa
N1 - Funding Information: Conflicts of interest: E. Heffler reports participation to advisory boards and personal fees from AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestl? Purina, Boheringer Ingheleim, and Valeas, outside the submitted work. G. W. Canonica reports grants as well as lecture or advisory board fees from A. Menarini, Alk-Abello, Allergy Therapeutics, AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Mylan, Merck, Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme, StallergenesGreer, UCB pharma, Uriach Pharma, Valeas, and ViborPharma. F. Blasi reports grants and personal fees from AstraZeneca, Chiesi, GSK, Pfizer and Insmed; grants from Bayer; and personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis, and Zambon, outside the submitted work. P. Paggiaro reports grants and personal fees from AstraZeneca, Chiesi, Novartis, and Sanofi; and personal fees from GlaxoSmithKline, Guidotti, and Mundipharma, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85106372715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106372715&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.04.011
DO - 10.1016/j.jaip.2021.04.011
M3 - Article
C2 - 33892172
AN - SCOPUS:85106372715
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
ER -